BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable
choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high …

Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are
introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment …

Wasay et al. New Oral Anticoagulants in Cerebral Venous Thrombosis https://doi.
org/10.5853/jos. 2019.00150 222 http://j-stroke. org to the discretion of the treating …

Cerebral venous thrombosis (CVT) affects approximately 15 people per million annually and
represents 0.5% of all stroke [1, 2]. Initiation of anticoagulation with heparin followed by …

Background: High level evidence for direct oral anticoagulants (DOACs) in patients with
cerebral venous thrombosis is lacking. We performed a systematic review and meta-analysis …

Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …

Background: Cerebral venous thrombosis (CVT) is an uncommon neurological condition
usually treated with heparin followed by oral vitamin K antagonists (VKAs). In patients with …

Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current
guidelines for CVT management support the initial use of unfractionated heparin or low …

Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major
cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of …

Objectives Current guidelines do not recommend direct oral anticoagulants (DOACs) to treat
cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We …